Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Enrollment on the treatment phase of the I-SPY 2 TRIAL
Completed a standard neoadjuvant chemotherapy regimen or assigned treatment on I-SPY 2 and planning definitive surgical resection. Participants who have discontinued assigned treatment on I-SPY 2, switched to standard of care, and have completed a standard neoadjuvant chemotherapy regimen are still considered eligible.
Pre-surgical imaging or clinical examination demonstrating residual disease in the breast. Participants with any extent of enhancement attributable to tumor on the pre-surgical MRI are eligible. No minimum extent of palpable tumor pre-surgery is required.
Willing to undergo bone marrow aspiration and blood specimen collection per protocol specifications
No clinical evidence of distant metastatic disease. Pre-chemotherapy staging scans are sufficient in the absence of any symptoms or subsequent clinical evidence suggesting distant metastases
Age 18 or over and are able to give informed consent
You may not be if
Individuals under the age of 18
Individuals who cannot understand and give informed consent. We will not be assessing decisional capacity; determination of ability to give informed consent will be at the discretion of the treating physician.
Clareo Health | Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer
